Clearside Biomedical, Inc. (CLSDQ)
OTCMKTS · Delayed Price · Currency is USD
1.090
-0.020 (-1.80%)
At close: Jan 16, 2026
Clearside Biomedical Revenue
Clearside Biomedical had revenue of $201.00K in the quarter ending September 30, 2025, a decrease of -80.64%. This brings the company's revenue in the last twelve months to $3.33M, down -56.78% year-over-year. In the year 2024, Clearside Biomedical had annual revenue of $1.66M, down -79.77%.
Revenue (ttm)
3.33M
Revenue Growth
-56.78%
P/S Ratio
1.71
Revenue / Employee
104.03K
Employees
32
Market Cap
5.71M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.66M | -6.56M | -79.77% |
| Dec 31, 2023 | 8.23M | 6.90M | 519.89% |
| Dec 31, 2022 | 1.33M | -28.25M | -95.51% |
| Dec 31, 2021 | 29.58M | 21.68M | 274.65% |
| Dec 31, 2020 | 7.89M | 5.72M | 263.28% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| American Oncology Network | 1.76B |
| Veradigm | 588.02M |
| Glass House Brands | 196.17M |
| Vaxart | 148.20M |
| Elite Pharmaceuticals | 122.89M |
| Silence Therapeutics | 25.83M |
| OpGen | 9.00M |
| Stem Cell Authority | 3.33M |
Clearside Biomedical News
- 7 weeks ago - Clearside Biomedical to Pursue Strategic Sale of its Business Through Voluntary Chapter 11 Process - GlobeNewsWire
- 5 months ago - Clearside Biomedical Announces Multiple Presentations on Suprachoroidal Delivery to be Featured at the 25th EURETINA Congress - GlobeNewsWire
- 6 months ago - Clearside Biomedical Announces Approval of XIPERE® Suprachoroidal Treatment for Uveitic Macular Edema in Canada - GlobeNewsWire
- 6 months ago - Clearside Biomedical Announces Plan to Explore Strategic Alternatives to Advance its Proprietary Suprachoroidal Space (SCS®) Delivery Platform and Promising Ophthalmology Pipeline - GlobeNewsWire
- 7 months ago - Clearside Biomedical Announces Multiple Presentations to be Featured at the Clinical Trials at the Summit Meeting - GlobeNewsWire
- 8 months ago - Clearside Biomedical to Participate in a Fireside Chat at the Stifel 2025 Virtual Ophthalmology Forum - GlobeNewsWire
- 8 months ago - Clearside Biomedical Announces First Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 9 months ago - Clearside Biomedical Data Featured in Six Presentations at Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting - GlobeNewsWire